Zydus, Bioeq Partner for US Macular Degeneration Drug NUFYMCO

• Zydus Lifesciences partners with Swiss Bioeq AG to commercialize NUFYMCO, an interchangeable biosimilar to Lucentis (ranibizumab), in the US.
• Zydus Lifesciences Global FZE will handle US commercialization, while Bioeq manages development, manufacturing, regulatory, and supply.
• NUFYMCO, a VEGF inhibitor, treats neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
• The drug's Biologics License Application (BLA) received US FDA approval on December 18, 2025.
• This collaboration expands Zydus's US biosimilar portfolio, aiming to provide affordable ophthalmology care.

Why It Matters: Zydus and Bioeq collaborate to bring an affordable macular degeneration biosimilar to the US market.